(Q26772881)

English

Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

0 references

1 reference

22 July 2020

Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis (English)

0 references

World Health Organization

1 reference

based on heuristic

inferred from abstract

polycythemia vera

1 reference

22 July 2020

1 reference

22 July 2020

essential thrombocytosis

1 reference

22 July 2020

diagnostic criteria

1 reference

based on heuristic

inferred from abstract

4

object named as

A Tefferi

0 references

author name string

T Barbui

1

0 references

J Thiele

2

0 references

A M Vannucchi

3

0 references

language of work or name

0 references

publication date

14 August 2015

3 references

6 March 2019

3 April 2019

22 July 2020

Blood Cancer Journal

3 references

6 March 2019

3 April 2019

22 July 2020

5

0 references

8

0 references

e337

0 references

copyright license

Creative Commons Attribution 4.0 International

3 references

Europe PubMed Central

6 March 2019

Europe PubMed Central

3 April 2019

Europe PubMed Central

22 July 2020

copyright status

0 references

on focus list of Wikimedia project

0 references

Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558589

7 April 2017

Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558589

7 April 2017

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558589

7 April 2017

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558589

7 April 2017

Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558589

7 April 2017

Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558589

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558589

7 April 2017

Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558589

7 April 2017

Age-related clonal hematopoiesis associated with adverse outcomes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558589

7 April 2017

Age-related mutations associated with clonal hematopoietic expansion and malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558589

7 April 2017

Guideline for investigation and management of adults and children presenting with a thrombocytosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558589

7 April 2017

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558589

7 April 2017

CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558589

9 May 2017

Effect of mutation order on myeloproliferative neoplasms

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558589

28 September 2017

Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558589

28 September 2017

Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558589

28 September 2017

Essential thrombocythemia vs. early/prefibrotic myelofibrosis: why does it matter

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558589

28 September 2017

An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558589

28 September 2017

Somatic mutations of calreticulin in myeloproliferative neoplasms

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558589

28 September 2017

Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558589

28 September 2017

Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558589

28 September 2017

Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558589

28 September 2017

Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558589

28 September 2017

Red cell mass measurement in patients with clinically suspected diagnosis of polycythemia vera or essential thrombocythemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558589

28 September 2017

Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558589

28 September 2017

European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558589

28 September 2017

Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558589

28 September 2017

Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558589

28 September 2017

Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558589

28 September 2017

Prodromal myeloproliferative neoplasms: the 2008 WHO classification

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558589

28 September 2017

Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558589

28 September 2017

The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558589

28 September 2017

Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558589

28 September 2017

Essential thrombocythemia or chronic idiopathic myelofibrosis? A single-center study based on hematopoietic bone marrow histology.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558589

28 September 2017

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558589

28 September 2017

The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra vera

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558589

28 September 2017

The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558589

28 September 2017

European consensus on grading bone marrow fibrosis and assessment of cellularity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558589

28 September 2017

How to interpret and pursue an abnormal complete blood cell count in adults

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558589

28 September 2017

The rise and fall of red cell mass measurement in polycythemia vera

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558589

28 September 2017

The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558589

28 September 2017

Standardization of bone marrow features--does it work in hematopathology for histological discrimination of different disease patterns?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558589

28 September 2017

Diagnostic impact of bone marrow histopathology in polycythemia vera (PV).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558589

28 September 2017

Polycythemia vera: myths, mechanisms, and management

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558589

28 September 2017

Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558589

28 September 2017

Aetiology and clinical significance of thrombocytosis: analysis of 732 patients with an elevated platelet count

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558589

28 September 2017

Thrombotic complications in essential thrombocythemia with relatively low platelet counts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558589

28 September 2017

Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558589

28 September 2017

The bone marrow in polycythemia vera

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558589

28 September 2017

Classification and staging of Ph-negative myeloproliferative disorders by histopathology from bone marrow biopsies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558589

28 September 2017

Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558589

31 May 2018

Reproducibility of the WHO histological criteria for the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558589

31 May 2018

Studies of the bone marrow in polycythemia vera and the evolution of myelofibrosis and second hematologic malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558589

31 May 2018

Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management

1 reference

https://api.crossref.org/works/10.1038%2FBCJ.2015.64

21 January 2018

Modification of British Committee for Standards in Haematology diagnostic criteria for essential thrombocythaemia

1 reference

https://api.crossref.org/works/10.1038%2FBCJ.2015.64

21 January 2018

WHO-histological criteria for myeloproliferative neoplasms: reproducibility, diagnostic accuracy and correlation with gene mutations and clinical outcomes.

1 reference

https://api.crossref.org/works/10.1038%2FBCJ.2015.64

21 January 2018

Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera.

1 reference

https://api.crossref.org/works/10.1038%2FBCJ.2015.64

21 January 2018

Presence of calreticulin mutations in JAK2-negative polycythemia vera.

1 reference

https://api.crossref.org/works/10.1038%2FBCJ.2015.64

21 January 2018

A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications.

1 reference

https://api.crossref.org/works/10.1038%2FBCJ.2015.64

21 January 2018

Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia.

1 reference

https://api.crossref.org/works/10.1038%2FBCJ.2015.64

21 January 2018

The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants

1 reference

https://api.crossref.org/works/10.1038%2FBCJ.2015.64

21 January 2018

Mutations and prognosis in primary myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FBCJ.2015.64

21 January 2018

U2AF1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with JAK2V617F and normal karyotype.

1 reference

https://api.crossref.org/works/10.1038%2FBCJ.2015.64

21 January 2018

SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML.

1 reference

https://api.crossref.org/works/10.1038%2FBCJ.2015.64

21 January 2018

Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis.

1 reference

https://api.crossref.org/works/10.1038%2FBCJ.2015.64

21 January 2018

An elevated venous haemoglobin concentration cannot be used as a surrogate marker for absolute erythrocytosis: a study of patients with polycythaemia vera and apparent polycythaemia

1 reference

https://api.crossref.org/works/10.1038%2FBCJ.2015.64

21 January 2018

Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis

1 reference

https://api.crossref.org/works/10.1038%2FBCJ.2015.64

21 January 2018

Masked polycythemia vera (mPV): results of an international study

1 reference

https://api.crossref.org/works/10.1038%2FBCJ.2015.64

21 January 2018

Masked polycythemia vera diagnosed according to WHO and BCSH classification.

1 reference

https://api.crossref.org/works/10.1038%2FBCJ.2015.64

21 January 2018

Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients.

1 reference

https://api.crossref.org/works/10.1038%2FBCJ.2015.64

21 January 2018

A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera.

1 reference

https://api.crossref.org/works/10.1038%2FBCJ.2015.64

21 January 2018

Initial (latent) polycythemia vera with thrombocytosis mimicking essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1038%2FBCJ.2015.64

21 January 2018

The significance of bone marrow biopsy and JAK2V617F mutation in the differential diagnosis between the "early" prepolycythemic phase of polycythemia vera and essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1038%2FBCJ.2015.64

21 January 2018

World Health Organization-defined classification of myeloproliferative neoplasms: morphological reproducibility and clinical correlations--the Danish experience

1 reference

https://api.crossref.org/works/10.1038%2FBCJ.2015.64

21 January 2018

The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FBCJ.2015.64

21 January 2018

High concordance in grading reticulin fibrosis and cellularity in patients with myeloproliferative neoplasms.

1 reference

https://api.crossref.org/works/10.1038%2FBCJ.2015.64

21 January 2018

Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome.

1 reference

https://api.crossref.org/works/10.1038%2FBCJ.2015.64

21 January 2018

Evolution of myelofibrosis in chronic idiopathic myelofibrosis as evidenced in sequential bone marrow biopsy specimens

1 reference

https://api.crossref.org/works/10.1038%2FBCJ.2015.64

21 January 2018

Dynamics of fibrosis in chronic idiopathic (primary) myelofibrosis during therapy: a follow-up study on 309 patients

1 reference

https://api.crossref.org/works/10.1038%2FBCJ.2015.64

21 January 2018

The importance of central pathology review in international trials: a comparison of local versus central bone marrow reticulin grading.

1 reference

https://api.crossref.org/works/10.1038%2FBCJ.2015.64

21 January 2018

Should a platelet limit of 600 x 109/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages

1 reference

https://api.crossref.org/works/10.1038%2FBCJ.2015.64

21 January 2018

The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients

1 reference

https://api.crossref.org/works/10.1038%2FBCJ.2015.64

21 January 2018

Classification of myeloproliferative disorders in the JAK2 era: is there a role for red cell mass?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558589

28 November 2018

Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification

1 reference

https://pubmed.ncbi.nlm.nih.gov/26832847

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Infrequent occurrence of MPL exon 10 mutations in polycythemia vera and post-polycythemia vera myelofibrosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/26832847

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reproducibility of histologic classification in nonfibrotic myeloproliferative neoplasia

1 reference

https://pubmed.ncbi.nlm.nih.gov/26832847

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The incidence of myelofibrosis in essential thrombocythaemia, polycythaemia vera and chronic idiopathic myelofibrosis: a retrospective evaluation of sequential bone marrow biopsies

1 reference

https://pubmed.ncbi.nlm.nih.gov/26832847

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Essential thrombocythemia with high hemoglobin levels according to the revised WHO classification

1 reference

https://pubmed.ncbi.nlm.nih.gov/26832847

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Diagnosis of essential thrombocythemia at platelet counts between 400 and 600x10(9)/L. Gruppo Italiano Malattie Mieloproliferative Croniche(GIMMC)

1 reference

https://pubmed.ncbi.nlm.nih.gov/26832847

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Diagnostic differentiation of essential thrombocythaemia from thrombocythaemias associated with chronic idiopathic myelofibrosis by discriminate analysis of bone marrow features--a clinicopathological study on 272 patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/26832847

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Value of bone marrow biopsy in the diagnosis of essential thrombocythemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/26832847

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Myelofibrosis in chronic myeloproliferative disorders. Incidence among subtypes according to the Hannover Classification

1 reference

https://pubmed.ncbi.nlm.nih.gov/26832847

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/26832847

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Grade of bone marrow fibrosis is associated with relevant hematological findings-a clinicopathological study on 865 patients with chronic idiopathic myelofibrosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/26832847

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/26832847

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/26832847

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Practical application and clinical impact of the WHO histopathological criteria on bone marrow biopsy for the diagnosis of essential thrombocythemia versus prefibrotic primary myelofibrosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/26832847

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Diagnosis according to World Health Organization determines the long-term prognosis in patients with myeloproliferative neoplasms treated with anagrelide: results of a prospective long-term follow-up

1 reference

https://pubmed.ncbi.nlm.nih.gov/26832847

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/BCJ.2015.64

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Dimensions Publication ID

0 references

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PMC publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PubMed publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q26772881&oldid=2221341954"